chrisvoncsefalvay/vaers-outcomes huggingface dataset:
After shot 1, I had severe brain fog and a flare-up of my sarcoidosis with itching shins, fatigue, swollen lymph nodes.   After shot 2, my system was initially fine. No reaction at all, in fact. But within 4 days, the sarcoidosis flare-up kicked in and has been building with nothing stopping it that normally works - rest being the big thing. I've slept 9-10 hours a night, plus naps as possible, and it has gotten progressively worse. Joints, lymph nodes in areas that aren't usually swollen joining the usual areas, facial swelling, itchy shins, and an incredible brain fog.   I am beginning a course of prednisone today.
approx 40min p/vax pt deltoid became edematous & reddened;pt c/o area feeling sore;no c/o fever;pt was given Advil for discomfort;6PM pt given advil for pain & ice applied to area;pt was brought to clinic;observed for rxn;
The child received #1 Tdap, #2 Influenza vacc in (L) arm, #3 MENACTRA on (L) arm. As 3rd needle was being removed, he fell forward across his knees, had moderate clonic movements, brief loss of awareness x < 30 sec with mild shaking of upper ext. - then came to with slight dizziness.
Child came for catch-up vaccines. Due DTaP and Polio. DTaP and Polio vaccines were given separately but TDaP should have been given due to age.
Had Tdap on 08/15/2006 left deltoid, next day left axilla lymph nodes swollen and sore.  Still sore today (08/17/2006). Lymph nodes still swollen.
sore injection site arm after each dose of the Moderna Covid-19 Primary Series Vaccine.; This spontaneous case was reported by a patient and describes the occurrence of VACCINATION SITE PAIN (sore injection site arm after each dose of the Moderna Covid-19 Primary Series Vaccine.) in a male patient of an unknown age who received mRNA-1273 (Spikevax) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received first dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Spikevax) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE PAIN (sore injection site arm after each dose of the Moderna Covid-19 Primary Series Vaccine.). At the time of the report, VACCINATION SITE PAIN (sore injection site arm after each dose of the Moderna Covid-19 Primary Series Vaccine.) outcome was unknown.            Concomitant medication details were not reported. Treatment details were not reported by the reporter.   This case was linked to MOD-2022-637953 (Patient Link).   Reporter did not allow further contact
Patient was administered a Moderna vaccine with an expiry date 10/15/2021.  She tolerated the injection well and monitored for 15min after injection.  No complications  or adverse events were noted.
mild itch; raised welt; mild injection site tenderness; mild injection site pain; This spontaneous case was reported by an other health care professional and describes the occurrence of INJECTION SITE PAIN (mild injection site pain), PRURITUS (mild itch), URTICARIA (raised welt) and INJECTION SITE PAIN (mild injection site tenderness) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 042L20A) for COVID-19 vaccination.     Concomitant products included Tylenol                                                        as needed and LEVOTHYROXINE for an unknown indication.    On 09-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Feb-2021, the patient experienced INJECTION SITE PAIN (mild injection site pain) and INJECTION SITE PAIN (mild injection site tenderness). On 17-Feb-2021, the patient experienced PRURITUS (mild itch) and URTICARIA (raised welt). At the time of the report, INJECTION SITE PAIN (mild injection site pain), PRURITUS (mild itch), URTICARIA (raised welt) and INJECTION SITE PAIN (mild injection site tenderness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No treatment information was provided.   Most recent FOLLOW-UP information incorporated above includes: On 20-Jun-2021: Followup was received on 20-Jun-2021. No new information was present in source document.
Chills; Fever; This is a spontaneous report from a contactable consumer (patient) via Covid-19 Adverse Event Self-Reporting Solution (COVAES).  A 53-year-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE) via an unspecified route of administration, administered in Arm Left on 25Mar2021 13:15 (lot number: EL3247; expiry date: unknown) at the age of 53-years-old, as dose 2, single, for Covid-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient had no known allergies. The patient previously received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE) on 04Mar2021 at 21:30 (lot number: EL3247) in arm left for Covid-19 immunisation. The patient was not pregnant at the time of vaccination. The vaccine was administered in a workplace clinic. The patient did not receive other vaccines within 4 weeks prior to the COVID vaccine. The patient did not receive other medications within 2 weeks of vaccination. The patient was not diagnosed with Covid-19 prior vaccination. The patient has not been tested for Covid-19 post vaccination. On 25Mar2021 23:30, the patient experienced chills and fever. The events were considered non-serious. The patient did not receive treatment for the events. Outcome of the events was recovering.  No follow-up attempts are needed. No further information is expected.
PATIENT REPORTS NAUSEA/VOMITING. GETS WORSE WITH ORENCIA INJECTION. LOST 12 LBS
Headache started around 9 pm Fever started around 10 pm Chills and body aches started around 10:30 pm Fever broke around 4 am Headache eased around 6 am Body aches eased around 6 am Fever returned around 10 am Body aches and headache returned around 11 am Dizziness started around 11 am All symptoms have been on and off since lasting for 2-3 hours, leaving for an hour and then returning again.  I have not taken any medication for this due to my blood pressure medications.
Within one day, Muscle pain in legs and muscle weakness in legs.  Legs felt "heavy" and weakness is progressive; pain resolved in about 2 weeks, balance/walking unsteady, trunk muscle weakness, fasiculations both quadriceps,  swelling of lower legs, espec. right, pins and needles feeling bottom of feet with pain walking diagnosed as peripheral neuropathy.  As of 7/10, muscle weakness in legs progressing and can't be on feet more than 20 minutes
head to toe rash-started approx 1wk to 10 days p/vax;fever in AM  & PM of unk degree for 3 days;t97.9 on 5AUG97 MD visit was given rx for pred;no longer a problem;
This case was reported by a physician via sales rep and described the occurrence of injection site erythema in a adult female patient who received BEXSERO. On an unknown date, the patient received BEXSERO. On an unknown date, an unknown time after receiving BEXSERO, the patient experienced injection site erythema, injection site swelling and injection site warmth. On an unknown date, the outcome of the injection site erythema, injection site swelling and injection site warmth were recovered/resolved. It was unknown if the reporter considered the injection site erythema, injection site swelling and injection site warmth to be related to BEXSERO. Additional details were provided as follows: The age at the time of reporting was 19 years. The age at vaccination was not reported. The patient received BEXSERO in an unknown arm. Limited information was provided by the sales representative from the physician. This case has been linked with case US2017026063, US2017026065 and US2017026064 as reported by same reporter.
Patient had swelling and redness from site of injection all the way to the elbow. It was notived 1 day after vacccine, but 2 days after, the swelling and redness started to reduce.
Intense pain remains in left arm; Intense pain remains in left arm and up into the neck; This is a spontaneous report from a non-contactable consumer, the patient. A 49-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration in the left arm on 09Apr2021 at 12:30 (at the age of 49-years-old), as a single dose for COVID-19 immunisation. Medical history was reported as none and the patient did not have a history of allergies to any food or medications or other products. The patient did not receive any other medications within two weeks prior to vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 09Apr2021 at 17:00, the patient experienced intense pain remains in left arm and up into the neck. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the event intense pain remains in left arm and up into the neck was recovering at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
broke out with sores; itch; This case was reported by a consumer via interactive digital media and described the occurrence of pain in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced pain and pruritus. On an unknown date, the outcome of the pain and pruritus were recovered/resolved.   It was unknown if the reporter considered the pain and pruritus to be related to Shingles vaccine.   Additional details were provided as follows: The case was reported by the patient. Age at vaccination was not reported. The patient got his/her 1st shingles vaccine and broke out with sores and itch for 3 weeks.  They clear at the time of reporting but did not know about taking the second.  The patient also asked anybody else had any side effects. No contact details were reported.
Pruritic rash began approximately 5 days after vaccine. Some improvement with Benadryl.  Patient denies any other associated symptoms.
Local swelling, erythema and pruritis over area of 7x6cm.  No shortness of breath, vomiting or changes in mental status.
pt calls and day and half later after getting the vaccine and complaining about hives and itching on all over her back.   she was advised to take Benadryl.  she also stated that she was having trouble when should would take deep breaths ( but breathing ok)   she was advised to contact her doctor, her doctor suggested Benadryl,  Pepcid and Zyrtec.
Next morning developed welts/blotches on both arms.  Called doctor who recommended Benadryl; Benadryl helped. Next day neck and back pain started; ached all over like if had the Flu.  Thursday had to leave work early because was so achy. On Sunday, spoke to doctor on call since pain and achiness continued; doctor specified he had the same problems with the vaccine and recommended stretching/exercising and alternating 2 Naproxen with 2 Tylenol.  As of today, neck still is aching; it felt like the gripe/bad case of flu.  Patient has headaches sporadically and fatigue.   Pain level has not changed since Sunday. Recovery is at 80%.
Nausea; fevers; chills; body ache; headache; muscle and joint pain; muscle and joint pain; fast heart rate of 92 at resting; injection site pain; extremely fatigue; weakness; This is a spontaneous report from a non-contactable consumer (patient). A 40-year-old female patient received BNT162B2 (Pfizer-Biontech Covid-19 Vaccine, Lot. elt9899) on an unspecified date, at single dose, for COVID-19 immunisation. Relevant medical history and concomitant medications were unknown. On an unspecified date, the patient experienced nausea, fevers, chills, body ache, headache, muscle and joint pain, fast heart rate of 92 at resting, injection site pain, extremely fatigue and weakness. Clinical outcome of the events was unknown at time of this report. The case was assessed as non-serious.   No follow-up attempts are possible. No further information is expected.
Patient collapsed immediately following the Gardasil shot.  She fell to her right side. Her mouth dropped open and her eyes were open. She was nonresponsive. She came to after a minute or two and said everything went black - sort of like she fainted but her eyes were not closed.
Asthma attack; shortness of breath; Tightness in chest; coughing; Sore arm; This spontaneous case was reported by a consumer and describes the occurrence of ASTHMA (Asthma attack), DYSPNOEA (shortness of breath), CHEST DISCOMFORT (Tightness in chest), COUGH (coughing) and PAIN IN EXTREMITY (Sore arm) in a 54-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 004M20A) for COVID-19 vaccination.     Concurrent medical conditions included Asthma (From birth), Postural orthostatic tachycardia syndrome (recent changes in status of chronic condition  with symptoms of fatigue lightheadedness, mental fog) since 2010, Drug allergy (Allergy to Imitrez), Contrast media allergy (CT dye), Drug allergy (Allergy to Zomig) and Drug allergy (Allergy to dioxicycline). Concomitant products included ESTRADIOL for Hormone therapy, ZOLPIDEM TARTRATE (AMBIEN) for Sleep difficult.    On 27-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-Jan-2021, the patient experienced ASTHMA (Asthma attack), DYSPNOEA (shortness of breath), CHEST DISCOMFORT (Tightness in chest), COUGH (coughing) and PAIN IN EXTREMITY (Sore arm). On 27-Jan-2021, ASTHMA (Asthma attack) had resolved. At the time of the report, DYSPNOEA (shortness of breath), CHEST DISCOMFORT (Tightness in chest) and COUGH (coughing) had resolved and PAIN IN EXTREMITY (Sore arm) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       (EMT) advised her to use asthma inhaler. Oxygen and blood pressure were monitored for 30 minutes.   This case was linked to US-MODERNATX, INC.-MOD-2021-081259 (E2B Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 18-May-2021: Pt height, weight, race/ethnicity and AE's updated.  Concomitant meds and history also provided.(the response received from the reporter for dose 2) On 02-Jun-2021: Follow up included no new information.; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-081259:2nd dose
tenderness in right arm for two days; This spontaneous case was reported by a consumer and describes the occurrence of TENDERNESS (tenderness in right arm for two days) in an 89-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030M20A) for COVID-19 vaccination.     Concurrent medical conditions included Arthritis. Concomitant products included PARACETAMOL (TYLENOL) for Arthritis, AMLODIPINE, ACETYLSALICYLIC ACID (BABY ASPIRIN), CALCIUM, UBIDECARENONE (COQ), FISH OIL, GLUCOSE, SODIUM CHLORIDE, SODIUM LACTATE (LACTATE 1 2 3), MAGNESIUM, SIMVASTATIN and LEVOTHYROXINE SODIUM (THYROXIN) for an unknown indication.    On 10-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Feb-2021, the patient experienced TENDERNESS (tenderness in right arm for two days). On 12-Feb-2021, TENDERNESS (tenderness in right arm for two days) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment medication was reported.   This case was linked to MOD-2021-097147 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 29-Apr-2021: Information about first dose event outcome and second dose events.
patent presented for a clinic visit, per ND Vaccine certificate states patient recived COVID Vaccine from a white drug #39 pharmacy prior to the age of 12 and before pediatric was approved.  received on  08/10/2021 08/31/2021  Per clinic visit today father voiced they lied about age for child to get vaccinated before the approved age
Headache and nauseousness consistently from day 3 after vaccine to present (two weeks later and continuing).
About 10 minutes after getting her immunization the patient returned to pharmacy saying she didn't feel good. Chief complaint was trouble breathing.  Patient looked like she was going to pass out so we help her to the floor. Patients legs were elevated and she was given and ice pack. Over the course of 10 minutes her breathing seemed to normalize. Patient also complained of  feeling spacey and light headed. EMSA did transport because of elevated blood pressure. When I checked on patient later that day she was at home and doing well.
Had the flu vaccine at 0800 10-30-2008 and approximately 1 1/2 hours after receiving the vaccine pt reported continuous dry cough then rhinitis, red watery eyes, sore itchy throat, slight shortness of breath and soreness in throat with breathing and especially with coughing returned to clinic, CBC w/diff was drawn, saline lock started and 1000cc Normal Saline bolus, also given was Benadryl 25mg IVP, Decadron 4mg IVP and Solumedrol 80mg IVP Lab results showed Patient improved with treatment and was dc'd to home in stable condition.
Both doses of vaccine caused a severe headache unbearable arthritis pain gout like symptoms in ankles lethargy and myalgia. Approximately 8 weeks after second vaccine I started having some slurred speech along with decreased dexterity in my right arm. By February I began to have difficulty swallowing and began losing weight. Then in June started with muscle twitching and lower extremity muscle cramping. In right arm and hips and spine have intense inflammation. This has now been diagnosed ALS. Walked 5 miles daily now and stood 8-12 hours a day as a healthcare professional. Have had flu shot every year with no problem until Shingrix involvement
Left thigh red, warm, tense and tender with streaking out from center. Treated with TMP/SMX 1 PO Bid x 7 days for cellulitis. Febrile to 100.4F.
Patient recived a dose of improperly stored PROQUAD; No additional adverse effect reported; This spontaneous case was received from an healthcare worker regarding to a patient of unknown age, gender and ethnicity. The patient's concurrent conditions, medical history, drug allergies and concomitant therapies were not reported.   On 27-JAN-2020, the patient was vaccinated with an improperly stored dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) (lot # S009756 with expiration date on 27-SEP-2020) administered subcutaneously for prophylaxis (strength and dose were not reported). The vaccine was reconstituted with a properly stored sterile diluent. The vaccine was exposed to a temperature between 6 °F and 14 °F (with an average temperature of 11.3 °F) for 12 hours and 30 minutes. No previous temperature excursion was reported. No adverse effect was reported. The report was received due to a data logger.   Albumin status has been verified for measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) (lot # S009756) to be recombinant human albumin (rHa).  This is one of several reports received from the same source.; Sender's Comments:  US-009507513-2005USA004443:
Redness, soreness and severe itching started February 3, 2021.  Progressed to include swelling of site.   As of February 6,  area of redness and swelling is now 8 by 10 centimeters.  Has not responded to anti-histamines and steroid cream and local heat or cold.
blurred vision, weakness in body, problem breathing 19DEC, fell 20DEC adm to hosp;CCU 21DEC98 moved to ICU 22DEC put on full life support GBS dx 1FEB taken off life support 4FEB98 transferred to another hosp;
fatigue; body aches; chills; This spontaneous case was reported by a consumer and describes the occurrence of FATIGUE (fatigue), MYALGIA (body aches) and CHILLS (chills) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) at an unspecified dose. On 12-Mar-2021, the patient experienced FATIGUE (fatigue), MYALGIA (body aches) and CHILLS (chills). Not Provided
5 Doses administered past the expiration date; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (5 Doses administered past the expiration date) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 049E21A) for COVID-19 vaccination.     No Medical History information was reported.  On 27-Oct-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 27-Oct-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (5 Doses administered past the expiration date). On 27-Oct-2021, EXPIRED PRODUCT ADMINISTERED (5 Doses administered past the expiration date) had resolved.      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  No treatment information was provided.   This case was linked to MOD-2021-380857 (Patient Link).
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a contactable reporter (Consumer or other non-HCP).  A 33-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 29Dec2021 as dose 3 (booster), single (Lot number: FL3209) at the age of 33 years for COVID-19 immunisation; COVID-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Asthma" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "recovering" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (unspecified date) Positive; (31Jul2022) Negative; (05Aug2022) Positive. Therapeutic measures were taken as a result of drug ineffective, covid-19 included PF-07321332, ritonavir (PAXLOVID) with treatment start date: 26Jul2022, treatment stop date: 31Jul2022.  No follow-up attempts are possible. No further information is expected.
Pt became weak and began to fall. Nurse lowered to ground. Fire department and other agency assisted; Pt aroused and c/o feeling jittery. Blood sugar 105; Provided food from car which was cotton candy and peanut butter and crackers. Pt states feels much better but but knee and neck hurt. Small abrasions on lateral aspect of knee and 2 bruises over bony areas of knee. Area cleaned with alcohol and band aide applied. Neck has full ROM. No abrasions on head. Patient and wife instructed to go to PCP or ER  after they leave. Wife states they will go to PCP,  Pt released in stable condition.
Pt developed Herpes Zoster-facial and LUQ. No ocular or otic involvement. Treated with IV nafcillin and acyclovir. Discharged home on oral acyclovir.
Induration x 8cm @ vax site lt thigh;refusal to walk;afeb;